• In February 2026, Repligen Corporation reported that fourth-quarter 2025 revenue rose to US$197.91 million from US$167.55 million a year earlier, swinging from a net loss to net income of US$13.29 million and turning prior per-share losses into positive earnings.
• Alongside this stronger profitability, the company issued relatively cautious 2026 guidance for revenue of US$810 million to US$840 million and diluted earnings per share of US$1.93 to US$2.01, which contrasted with its recent outperformance versus earlier expectations.
• Next, we’ll examine how Repligen’s better-than-expected 2025 results but cautious 2026 guidance affect its M&A- and margin-focused investment narrative.

Uncover the next big thing with 30 elite penny stocks that balance risk and reward.

Repligen Investment Narrative Recap

To own Repligen, you need to believe bioprocessing demand for biologics and newer modalities will keep supporting solid consumables and equipment revenue, and that management can keep lifting margins without overextending on spending or M&A. The Q4 2025 beat and return to profitability help the near term margin story, but the more measured 2026 guidance means the biggest short term catalyst is execution against these targets, while funding pressure on smaller biotech customers remains a key risk.

The most relevant recent announcement is the 2026 outlook calling for US$810 million to US$840 million of revenue and 15.1% to 15.5% operating margin. Against the strong 2025 beat, this guidance frames how much confidence you place in Repligen’s ability to grow across Proteins, Analytics, Chromatography, and Filtration while still expanding margins, despite gene therapy headwinds, tariff pressures, and uneven capital equipment demand.

Yet even with improving earnings, investors should be aware of how continued biotech funding weakness and customer concentration could still...

Repligen's narrative projects $1.0 billion revenue and $140.0 million earnings by 2028.

Uncover how Repligen's forecasts yield a $190.89 fair value, a 43% upside to its current price.

Exploring Other Perspectives

The lowest analysts were already cautious, assuming revenue would reach about US$1.0 billion and earnings US$128.6 million by 2028, and this new guidance could either challenge that pessimism or reinforce concerns about macro pressure and customer concentration, so you should expect views on Repligen to stay very divided and consider how your own expectations compare.

Explore 3 other fair value estimates on Repligen - why the stock might be worth just $160.90!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Repligen research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Repligen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Repligen's overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Outshine the giants: these 23 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.